Official Title
A Randomized Double Blind, Placebo-Controlled Study of Auxora for the Treatment of Severe COVID-19 Pneumonia (CARDEA)
Brief Summary

Part 1 of this trial enrolled 30 patients to receive Auxora (formerly CM4620) in a 2:1 randomized, open label trial of patients with severe and critical COVID-19 pneumonia. Part 2 will consist of a randomized, double blind, placebo-controlled (RCT) study that will evaluate efficacy, safety, and the pharmacokinetic profile of Auxora in patients with severe COVID-19 pneumonia. The number of patients with an imputed PaO2/FiO2 >200 randomized into the study will be capped at 26. 320 patients with a PaO2/FiO2 ≤200 will be enrolled. Patients with an estimated PaO2/FiO2 of 75-200 will be stratified to ensure balanced randomization between the Auxora and placebo arms. Subgroup analyses will be performed to explore how time to recovery is influenced by baseline variables and to evaluate the treatment effect at different levels of each of these variables. The dose of Auxora will be 2.0 mg/kg (1.25 mL/kg) administered at 0 hour, and then 1.6 mg/kg (1 mL/kg) at 24 hours and 1.6 mg/kg (1 mL/kg) at 48 hours from the SFISD. The dose of placebo will be 1.25 mL/kg administered at 0 hour and then 1 mL/kg at 24 hours and 1 mL/kg at 48 hours from the SFISD. Remdesivir, corticosteroids and convalescent plasma will be allowed. The infusion of Auxora will start within 12 hours from the time the patient or LAR provides informed consent. Efficacy analyses will be presented by treatment group (Auxora vs Placebo) based on the Efficacy Analysis Set of the imputed PaO2/FiO2 ≤200 subgroup, except where it is specified otherwise. The statistical analysis approach will be designed to assess the significance of the primary and first secondary endpoint using the Benjamini and Hochberg method to control the overall trial level alpha level.


Drug: Auxora

Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
Other Name: CM4620-Injectable Emulsion (IE)

Drug: Placebo

Placebo will be given at 1.25 mL/kg on Day 1 and then 1.0 mL/kg on Days 2 and 3. All doses of placebo will be administered intravenously over 4 hours.
Other Name: Placebo-Injectable Emulsion

Eligibility Criteria

Inclusion Criteria:

1. Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain
reaction (PCR) or other commercial or public health assay in any specimen, as
documented by either of the following:

- PCR positive in sample collected < 72 hours prior to randomization;

- PCR positive in sample collected ≥ 72 hours prior to randomization, with
inability to obtain a repeat sample (e.g. due to lack of testing supplies, or
limited testing capacity, or results taking >24 hours, etc.) or progressive
disease suggestive of ongoing SARS-CoV-2 infection;

2. At least 1 of the following symptoms: Fever, cough, sore throat, malaise, headache,
muscle pain, dyspnea at rest or with exertion, confusion, or respiratory distress;

3. At least 1 of the following signs at Screening or noted in the 24 hours before

- PaO2/FiO2 ≤200 when receiving supplemental oxygen. The PaO2/FiO2 may be estimated
from pulse oximetry (Appendix 1) or determined by arterial blood gas;

- If SpO2 ≥97%, must be receiving 10L or more of supplemental oxygen;

4. The presence of a respiratory infiltrate or abnormality consistent with pneumonia that
is documented by either a chest X-ray or computerized tomography scan of the lungs;

5. The patient is ≥ 18 years of age;

6. A female patient of childbearing potential must not attempt to become pregnant for 39
months, and if sexually active with a male partner, is willing to practice acceptable
methods of birth control for 39 months after the last dose of CM4620-IE;

7. A male patient who is sexually active with a female partner of childbearing potential
is willing to practice acceptable methods of birth control for 39 months after the
last dose of CM4620-IE. A male patient must not donate sperm for 39 months;

8. The patient is willing and able to, or has a legal authorized representative (LAR) who
is willing and able to, provide informed consent to participate, and to cooperate with
all aspects of the protocol.

Exclusion Criteria:

1. Expected survival or time to withdrawal of life-sustaining treatments expected to be
<7 days.

2. Do Not Intubate order;

3. Home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for
continuous positive airway pressure or bi-level positive airway pressure (CPAP/BIPAP)
used solely for sleep-disordered breathing;

4. PaO2/FiO2 ≤75 at the time of Screening. The PaO2/FiO2 may be estimated from pulse
oximetry (Appendix 1) or determined by arterial blood gas;

5. Noninvasive positive pressure ventilation;

6. Invasive mechanical ventilation via endotracheal intubation or tracheostomy;

7. Extracorporeal membrane oxygenation (ECMO);

8. Shock defined by the use of vasopressors;

9. Multiple organ dysfunction or failure;

10. Positive Influenza A or B testing if tested as local standard of care;

11. The patient has a history of:

1. Organ or hematologic transplant;

2. HIV;

3. Active hepatitis B, or hepatitis C infection;

12. Current treatment with:

1. Chemotherapy;

2. Immunosuppressive medications or immunotherapy (Section 5.3 for list of
prohibited immunosuppressive medications and immunotherapy) at the time of

3. Hemodialysis or Peritoneal Dialysis;

13. Have a history of venous thromboembolism (VTE) (deep vein thrombosis [DVT] or
pulmonary embolism [PE]) within 12 weeks prior to screening or have a history of
recurrent (> 1) VTE;

14. The patient is known to be pregnant or is nursing;

15. Currently participating in another study of an investigational drug or therapeutic
medical device at the time of consent;

16. Allergy to eggs or any of the excipients in study drug.

Eligibility Gender
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
United States

Long Beach Memorial
Long Beach, California, United States

University of Southern California / LA County
Los Angeles, California, United States

Sharp Memorial San Diego
San Diego, California, United States

National Jewish Health / St. Joseph's Hospital
Denver, Colorado, United States

Northwestern University
Chicago, Illinois, United States

Baton Rouge General
Baton Rouge, Louisiana, United States

Maine Medical Center
Portland, Maine, United States

Brigham and Women's Hospital
Boston, Massachusetts, United States

Henry Ford Hospital
Detroit, Michigan, United States

Sinai Grace
Detroit, Michigan, United States

Methodist Hospital
Saint Louis Park, Minnesota, United States

Regions Hospital
Saint Paul, Minnesota, United States

Texas Tech University Medical Center
El Paso, Texas, United States

John Peter Smith Hospital
Fort Worth, Texas, United States

Houston Methodist Hospital
Houston, Texas, United States

Virginia Commonwealth University
Richmond, Virginia, United States

Aurora Baycare
Green Bay, Wisconsin, United States

Sudarshan Hebbar, MD, Study Director
CalciMedica, Inc.

CalciMedica, Inc.
NCT Number
Calcium release-activated calcium channel (CRAC) inhibitors
MeSH Terms